Kulchenko N.G. –MD, PhD, urologist, senior lectures of the departmens of histology, cytology and embryology, Medical Institute of Peoples' Friendship University of Russia (RUDN University), firstname.lastname@example.org, ORCID 0000-0002-4468-3670
Yatsenko E.V. –MD, PhD, urologist, ultrasound medical specialist, deputy chief physician of Medical Clinic «Medicos», email@example.com, ORCID 0000-0002-7255-6679
Contacts: Yatsenko Ekaterina Vasilievna, firstname.lastname@example.org
Objective. The prevalence of chronic prostatitis in the world ranges from 2.2% to 9.7%.
Material. Chronic pelvic pain syndrome in chronic prostatitis is more than 90-95%. Therefore, the main place among the drugs for the treatment of acute and chronic prostatitis is occupied by nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation.
Results. The emergence of new modified drugs, such as «OKI» – Ketoprofen lysine salt, with high speed, significantly expands the possibilities of complex treatment of prostatitis. Due to good tolerability, and virtually no effect on the gastrointestinal tract.
Conclusion. The drug «OKI» – Ketoprofen lysine salt is promising for long – term therapy of chronic prostatitis and other inflammatory diseases in men.
Key words: chronic prostatitis, chronic pelvic pain, Кetoprofen lysine salt, nonsteroidal anti-inflammatory drugs.
For citation: Kulchenko N.G., Yatsenko E.V.. The role of anti-inflammatory therapy in the treatment of acute and chronic prostatitis. Features of innovative Ketoprofen molecule. Literature review. Experimental and clinical urology 2019;(3):158-163